Suppression of Ocular Scarring by RNA Interference
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2006 - March 31, 2009
Grant ID
G2006014
Goals
This project proposes to employ RNA interference (RNAi) technology to target CTGF. It is hoped that silencing of the growth factor will help block the scarring action. The efficacy and consequence of the siRNAs will be studied in cultured conjunctival fibroblasts.
Summary
Connective tissue growth factor (CTGF) is an important mediator of wound healing in various tissues. In the eye, CTGF has been implicated in corneal wound healing, and subconjunctival scarring following glaucoma surgery. Investigation in an ocular inflammation/fibrosis model in mouse will be followed to determine whether downregulation of CTGF would reduce inflammation and scarring. The current proposal is highly significant for its clinical impact since excessive scarring is often a major cause of impaired vision and blindness. Results obtained from this application may lead to novel therapeutic modalities to prevent inflammation and scarring after glaucoma surgery and in eye diseases including corneal opacities.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester